07:00 , Sep 24, 2015 |  BC Innovations  |  Strategy

Full speed AMED

In the five months since the Japan Agency for Medical Research and Development (AMED) opened its doors, the organization has created a network of 80 Japanese medical schools and hospitals to predict what the future...
07:00 , Aug 6, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Leukemia Inhibitor of DNA binding 3 (ID3) Studies in cell culture suggest that increasing ID3 expression could be useful for treating acute lymphoblastic leukemia (ALL)....
07:00 , Apr 10, 2006 |  BioCentury  |  Finance

Lion chronicles

Lion chronicles...
08:00 , Nov 17, 2003 |  BC Week In Review  |  Company News

PheneX AG, Lion bioscience deal

Nuclear receptor specialist PheneX acquired the assets that made up LIO's iD3 nuclear receptor drug discovery unit. LIO discontinued its iD3 group at the end of 2002. PheneX AG , Heidelberg, Germany   Lion bioscience...
08:00 , Nov 13, 2003 |  BC Extra  |  Company News

PheneX buys Lion bioscience discovery assets

Nuclear receptor specialist PheneX (Heidelberg, Germany) acquired from Lion bioscience (FSE:LIO; LEON) the assets that made up LIO's iD3 nuclear receptor drug discovery unit. LIO discontinued its iD3 group at the end of 2002. PheneX's...
07:00 , Oct 14, 2002 |  BioCentury  |  Strategy

Europe's restructuring

Europe's restructuring...
07:00 , Oct 14, 2002 |  BioCentury  |  Strategy

Europe's tight corset

European companies are starting to feel the pinch from both the capital markets and the slowdown in pharma partnering. Over the last three months, Europe has seen only 13 pharma deals - with none of...
07:00 , Sep 9, 2002 |  BC Week In Review  |  Company News

Lion bioscience bioinformatics, genomics news

LEON said it will terminate its iD3 drug discovery business by the end of the year in order to focus on its bioinformatics business. LEON expects the move to save it up to $20 million...
07:00 , Sep 9, 2002 |  BioCentury  |  Finance

Ebb & Flow

After slipping 2% last week, the BioCentury 100 index shed 8% over the past two weeks, sucking a lot of air out of the biotech rally that began on July 12. The group remains up...
07:00 , Sep 6, 2002 |  BC Extra  |  Company News

Lion ends discovery business

Lion bioscience (NMarkt:LIO; LEON) said it will terminate its iD3 drug discovery business by the end of the year in order to focus on its bioinformatics business and reach break even by the end of...